Arsenal Capital Partners has acquired Cello Health plc

Arsenal Capital Partners, a specialised private equity firm investing in healthcare and industrials companies, has acquired Cello Health plc, the global healthcare-focused advisory firm.

Cello Health is a global healthcare-focused advisory firm comprised of a set of leading scientific, commercial advisory and digital delivery capabilities. Cello Health currently services 24 of the top 25 pharmaceutical clients globally, as well as a wide range of biotech, diagnostics, devices and other key non-healthcare clients. Cello Health enables clients to commercialise, differentiate their assets, and drive brand success in ever more complex global markets. The business delivers its services through nearly 1,000 highly skilled professionals, utilising latest thinking, technology and digital solutions. Cello Health delivers its services from an office network in the UK and USA, with hub offices in New York City, Philadelphia, New Jersey, London, Edinburgh, and Farnham.

The acquisition of Cello Health provides the foundation for a new enterprise to enable healthcare and biopharmaceutical clients to maximise the value of their products. In doing so, it aims to help clients accelerate and optimise patient access to medical and technological advances that have a transformative effect on patient’s lives. Through a series of investments to acquire, invest in and develop best-in-breed companies, the new enterprise that is backed by Arsenal is assembling a differentiated set of capabilities across critical domains including strategy and insights, evidence generation, data and analytics, and communications – all rooted in world-class science and enabled by the latest technology.

Rothschild & Co advised on the acquisition of this transaction. For further detail please contact Karen Dawaf.

Contact the deal team